SABR effective against oligometastatic disease

Data from a comparative phase II study reveal improvements in progression-free survival among patients with oligometastatic non-small-cell lung cancer (≤5 metastases) receiving consolidative stereotactic ablative radiotherapy (SABR) plus maintenance chemotherapy after induction chemotherapy, relative to those receiving chemotherapy alone (9.7 months versus 3.5 months; P = 0.01). SABR, delivered to all disease sites, had no marked effect on the risk of adverse events, indicating a need for further trials of this approach in larger cohorts.